SUMMARY The effects of chronic tolbutamide treatment were examined in a diabetic animal model in which abnormal myocardial function and composition have previously been demonstrated. Eight diabetic dogs were given tolbutamide 250 mg/day orally and compared with seven untreated diabetics, five healthy dogs receiving tolbutamide, and eight normal controls. After one year, resting hemodynamic studies in the intact anesthetized state showed that treated diabetic dogs had a significantly higher left ventricular end-diastolic pressure of 12.1 ± 1.3 mm Hg associated with normal end-diastolic volume, compared to 6.1 ± 0.8 mm Hg in untreated diabetics (P < 0.01) and 6.3 ± 0.5 in normals. Stroke work and ejection frac-THE USEFULNESS OF ORAL HYPOGLYCEMIC AGENTS in the treatment of diabetes mellitus has been controversial since the initial reports of enhanced cardiovascular mortality in patients so treated.1 2 Although the acute effects of tolbutamide on the myocardium have been described in animals and man,3 there has been no study of the myocardial response to chronic administration of tolbutamide in diabetes.
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In a chronic animal model of mild diabetes, we have previously observed abnormal left ventricular function without significant coronary artery disease, associated with accumulation of periodic acid-Schiff positive glycoprotein in the myocardial interstitium and cell triglyceride increments. 8 This study was performed to examine the effects of chronic administration of tolbutamide, at doses which virtually normalized glucose tolerance, on the altered myocardial function and composition associated with experimental diabetes.
Methods
Healthy male mongrel dogs, 2-3 years of age, were selected for study. The dogs were dewormed and treated with distemper vaccine; they had no clinical evidence of disease in eight weeks of observation before the study began. Blood samples were negative for heart worms and both hematocrit and serum albumin were initially normal. All groups received the same diet consisting of 8% fat, 22% protein, 58% carbohydrate, 9% ash and 3% crude fiber.
Group I consisted of eight normal controls. Group with the dye dilution technique14 15 and end-diastolic volume has been correlated with the angiographic method.'6 17 A Swan-Ganz thermodilution catheter tip was placed in the main pulmonary artery and 10 ml of room temperature normal saline was injected as a bolus into the right atrium through the proximal lumen. Change of temperature was detected by the thermistor in the pulmonary artery and displayed on the recorder through a Wheatstone bridge; the area of the curve was computed manually for cardiac output calculation. Left ventricular ejection fraction was obtained in duplicate from the left ventricular washout curves obtained just above the aortic valve. Five ml cold saline was injected as a bolus into the inflow site of the ventricle; adequate mixing at this site has been described in our previous report.8 End-diastolic volume was calculated from the ratio of stroke volume and ejection fraction and expressed per kg body weight. Stroke work index in g.m/kg was calculated from the product of stroke volume per kg and the mean left ventricular systolic pressure minus end-diastolic pressure X 0.0136. The ratio of left ventricular end-diastolic pressure and volume was used as a simple index of wall stiffness at end diastole.
To evaluate the contractile state of the ventricle in vivo we employed an index which normalizes left ventricular dP/dt max for 1) the maximal isovolumic pressure (MIP) and 2) the circumferential fiber length (2irr), assuming a spherical shape at the end of the systolic isovolumic period and deriving the radius from the end-diastolic volume. The formula'8 is dP/dt max/MIP 2irr Left ventricular function was assessed during volume expansion.8 A second catheter was introduced into the ventricle and normal saline was infused at a rate of 50 ml/min. Left ventricular end-diastolic pressure was continuously recorded at high sensitivity while cardiac output and left ventricular volumes were determined rapidly in duplicate after three to four minutes of infusion when the animals were in a steady state as judged by heart rate, aortic pressure and ventricular end-diastolic pressure.
Metabolic and Histologic Studies
Approximately one hour following these studies, a thoracotomy was performed and the heart was arrested with iced Ringer's solution. Samples of myocardium were rapidly taken from the periapical region and divided into outer and inner layers. The outer layer was carefully trimmed of epicardial adipose tissue. All samples were placed in liquid nitrogen and homogenized in phosphate buffer. Lipids were extracted by the Folch procedure for determination of triglyceride,'0 cholesterol'1 and phospholipid.'2 Separate portions of these samples were homogenized and electrolytes extracted for 48 hours in distilled water. Potassium and sodium were determined on an Auto Analyzer system with a flame attachment. Water content was calculated from the wet weight-dry weight difference after the samples were dried in an oven at 100°C to constant weight. Statistical analyses included analysis of variance followed by Dunnett's multiple comparison test. '8 Sections were taken from the left ventricular myocardium and the left coronary artery for histochemical examination by the pathologist without knowledge of the diagnosis. These examinations included periodic acid-Schiff after treating twice with diastase to prevent staining of glycogen.20 Also, 12-15 specimens for electron microscopy were rapidly fixed in cold glutaraldehyde buffered with phosphate. The tissue was then washed, postfixed in osmium, exposed to lead and uranyl acetate, and embedded in epon.
Results
The diabetic animals (groups III and IV) were observed for 10-12 months after the initial alloxan dose and compared with the normal dogs (group I) observed for a similar duration. The tolbutamide control group (group II) was treated for 7-9 months, which was comparable to the duration of treatment in group IV. Body weight, hematocrit and serum albumin at the terminal study did not differ significantly from the control period in any group. There were no animals with heart worms at postmortem examination.
Fasting plasma glucose remained in the normal range in both diabetic groups before and after the induction of diabetes (table 1). The normal and tolbutamide control groups also had normal fasting plasma glucose. In the latter, no hypoglycemia was observed in fasting samples, presumably because the peak action of the drug was during the postprandial period. The glucose clearance was significantly reduced one month after the last dose of alloxan in both diabetic groups and remained reduced in the untreated dogs of group III throughout the observation period. In those treated with tolbutamide there was significant improvement of glucose intolerance toward normal. The clearance constant remained normal in the tolbutamide control group.
Tolbutamide blood levels were assayed after six months of treatment in groups II and IV. Peak serum levels after drug ingestion at meal time averaged 38 ± .9 ,gg/ml at four hours and were similar in both groups ( fig. 1 ). This level approximated the values reported in humans after an oral dose of 500 mg tolbutamide.2'
The resting hemodynamic data are summarized in table 2. Heart rate and aortic pressures were not significantly different in the four groups but there was a significant elevation of left ventricular end-diastolic pressure in the tolbutamide treated diabetics at rest compared to normals (P < 0.01). In the untreated diabetics, left ventricular enddiastolic pressure was normal. There was no significant difference in left ventricular end-diastolic volume, stroke work, ejection fraction and contractility index at rest in the four groups. The ratio of left ventricular end-diastolic pressure and volume was increased in the tolbutamide-diabetic group, but not significantly. In the tolbutamide control group the modest elevation of end-diastolic pressure was accompanied by a nearly proportional increase of end-diastolic volume. The enhanced end-diastolic pressure in the tolbutamide-diabetic group despite a normal end-diastolic volume was consistent with an interpretation of increased diastolic stiffness of the ventricle. This could not be accounted for by hypertrophy since ventricular weights were within the normal range in all dogs.
To examine the response to volume expansion, 200 ml of saline was infused acutely into the left ventricular chamber over a four minute period. There was no significant change On electron microscopy, lipid accumulation was observed in group IV with fat particles interspersed between myofibrils in a focal distribution ( fig. 3) , which was not apparent in the other three groups. The lipid particles, associated with pockets of glycogen particles, were in most cardiac response to chronic tolbutamide use, then these studies would not be applicable to humans with elevated fasting blood glucose. However, such diabetics appear to have myocardial abnormalities marked by triglyceridese 31 and interstitial glycoprotein accumulation.31 32 Since the former at least, is intensified by tolbutamide treatment in this animal model with chemical diabetes, the abnormal metabolism of myocardium in human hyperglycemic diabetics may be similarly affected.
